Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 66 articles: HTML format

Single Articles

January 2027
1. WU Y, Ma N, Wang N, Liu X, et al
   Resveratrol induces ferroptosis to repress malignant progression of lung cancer cells.
   Oncol Rep. 2027;57:2.
   PubMed     Abstract available
   
   
   December 2026
2. XU Z, Shen J, Lin Y, Shi H, et al
   CHCHD2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma: Insights from pan?cancer multi?omics and functional studies.
   Oncol Rep. 2026;56:207.
   PubMed     Abstract available
   
   
   November 2026
3. WU S, Zhang W
   Effect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non?small cell lung cancer cells.
   Oncol Rep. 2026;56:184.
   PubMed     Abstract available
   
   
   
4. LAI H, Sun K, Mu T, Liu X, et al
   Mitochondrial mechanisms underlying spatial immune phenotypes in non?small cell lung cancer: Implications for ICI response and cold?to?hot tumor conversion (Review).
   Oncol Rep. 2026;56:196.
   PubMed     Abstract available
   
   
   
5. LI X, Ma Y
   PINK1 promotes the progression of lung squamous cell carcinoma through the FAK/AKT/RhoA/vinculin pathway.
   Oncol Rep. 2026;56:195.
   PubMed     Abstract available
   
   
   October 2026
6. XU S, Chang X, Wu X, Wang F, et al
   HDAC1 promotes lung adenocarcinoma progression via the nuclear accumulation of beta?catenin.
   Oncol Rep. 2026;56:169.
   PubMed     Abstract available
   
   
   
7. BAI X, Yang Y, Luo Y, Jing P, et al
   Combination of lonidamine with devimistat induces synergistic antitumor effects in lung cancer via multifaceted disruption of cellular energy metabolism.
   Oncol Rep. 2026;56:178.
   PubMed     Abstract available
   
   
   
8. ZHANG Y, Shang Y, Zeng H, Ning R, et al
   Research progress on lactate metabolism in lung cancer: Tumorigenesis, drug resistance and clinical translation (Review).
   Oncol Rep. 2026;56:181.
   PubMed     Abstract available
   
   
   
9. WANG L, Feng Y, Liu Q
   Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non?small cell lung cancer (Review).
   Oncol Rep. 2026;56:182.
   PubMed     Abstract available
   
   
   September 2026
10. ZHANG Q, Sun Y, Zhuang Y, Xu S, et al
    M2?TAM?derived exosomal miR?491?3p modulates UBE2D3 and promotes the proliferation, migration and invasion of lung cancer cells.
    Oncol Rep. 2026;56:159.
    PubMed     Abstract available
    
    
    August 2026
11. ZHOU Y, Li R, Chen X, Zhang C, et al
    A fibroblast activation protein degrader enhances cisplatin sensitivity in non?small cell lung cancer.
    Oncol Rep. 2026;56:145.
    PubMed     Abstract available
    
    
    July 2026
12. QU F, Tong J, Qian W, He Q, et al
    Immune network remodeling driven by ferroptosis: Bidirectional interaction mechanisms among multiple immune cells in the lung cancer immune microenvironment (Review).
    Oncol Rep. 2026;56:135.
    PubMed     Abstract available
    
    
    
13. GUO Z, Li X, Suo P, Lin Z, et al
    Targeting lung cancer with tanshinones: Current mechanistic evidence and emerging opportunities (Review).
    Oncol Rep. 2026;56:136.
    PubMed     Abstract available
    
    
    June 2026
14. ZHOU Y, Ma J, Zhang J, He L, et al
    [Expression of Concern] Pifithrin?mu is efficacious against non?small cell lung cancer via inhibition of heat shock protein 70.
    Oncol Rep. 2026;55:118.
    PubMed     Abstract available
    
    
    May 2026
15. HU P, Li A
    ACSBG1?driven lipid reprogramming unveiled: A fatty acid metabolism?associated prognostic model for lung adenocarcinoma.
    Oncol Rep. 2026;55:82.
    PubMed     Abstract available
    
    
    April 2026
16. KOBAYASHI M, Konno C, Shimizu A, Kobayashi M, et al
    Tumor?associated glucocorticoid inhibition by mifepristone reduces polymorphonuclear myeloid?derived suppressor cells and promotes antitumor immunity in triple?negative breast cancer?bearing mice.
    Oncol Rep. 2026;55:60.
    PubMed     Abstract available
    
    
    
17. JIN S, Zhang D, Liao Z, Yu L, et al
    TRIM46 deficiency?induced DNA damage enhances the sensitivity of cisplatin in non?small cell lung cancer by regulating the Akt signaling pathway.
    Oncol Rep. 2026;55:58.
    PubMed     Abstract available
    
    
    
18. GUO M, Li H, Zhao Z, Wang Y, et al
    Suppressive role of SCN4B in the epithelial?mesenchymal transition of lung adenocarcinoma.
    Oncol Rep. 2026;55:68.
    PubMed     Abstract available
    
    
    March 2026
19. SHARMA U, Song J, Kandu H, Zhu Y, et al
    Advances in targeting KRAS mutations: A promising approach for the treatment of non?small cell lung cancer (Review).
    Oncol Rep. 2026;55:39.
    PubMed     Abstract available
    
    
    
20. MA H, Li L, Jiao C, Cheng Y, et al
    

    Immunotherapy after EGFR?TKI treatment in advanced non?small cell lung cancer: Current status and future perspectives (Review)

    .
    Oncol Rep. 2026;55:44.
    PubMed     Abstract available
    
    
    
21. JIANG J, Dong G, Zhang Z, Lei X, et al
    Recapitulating lung cancer metastasis in vitro: Advances in organoid models and challenges in clinical translation (Review).
    Oncol Rep. 2026;55:49.
    PubMed     Abstract available
    
    
    February 2026
22. JIN L, Wei L, Hua J, Zhang R, et al
    Inhibition of primary ciliogenesis enhances efficacy of EGFR?TKIs against non?small cell lung cancer cells.
    Oncol Rep. 2026;55:30.
    PubMed     Abstract available
    
    
    January 2026
23. WANG K, Li Y, Guo Z, Song L, et al
    Role of the SOX family in non?small cell lung cancer: Molecular mechanisms and therapeutic implications (Review).
    Oncol Rep. 2026;55:19.
    PubMed     Abstract available
    
    
    
24. YIN Y, Tang L, Shi L
    [Corrigendum] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin?related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
    Oncol Rep. 2026;55:21.
    PubMed     Abstract available
    
    
    December 2025
25. ZHENG WW, Ding JX, Liang YX, Ye L, et al
    Hydroxypropyl?beta?cyclodextrin/thymoquinone inclusion complex inhibits non?small cell lung cancer progression through NF?kappaB?mediated ferroptosis.
    Oncol Rep. 2025;54:157.
    PubMed     Abstract available
    
    
    
26. ZHAO C, Xu Y, Zhang Y, Tan W, et al
    [Expression of Concern] Downregulation of miR?145 contributes to lung adenocarcinoma cell growth to form brain metastases.
    Oncol Rep. 2025;54:158.
    PubMed     Abstract available
    
    
    November 2025
27. LEI Y, Guo W, Chen B, Chen L, et al
    [Retracted] Tumor?released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non?small cell lung cancer.
    Oncol Rep. 2025;54:140.
    PubMed     Abstract available
    
    
    
28. WU A, Ni Y, Zhou Y, Shi J, et al
    Emerging dual role of ferroptosis in lung cancer (Review).
    Oncol Rep. 2025;54:141.
    PubMed     Abstract available
    
    
    
29. TANG C, Hahm E, Bae S, Kang JS, et al
    [Expression of Concern] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin?related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
    Oncol Rep. 2025;54:146.
    PubMed     Abstract available
    
    
    
30. WU X, Qu C, Ouyang Y, Yang L, et al
    T cell exhaustion?related gene CD79B predicts prognosis, inhibits malignant progression and promotes tumor?associated macrophage M1?like polarization in lung adenocarcinoma.
    Oncol Rep. 2025;54:144.
    PubMed     Abstract available
    
    
    
31. LV Q, Xu J, Hu N, Zhao Y, et al
    Lactylation modification in lung cancer: A review of current research and future directions (Review).
    Oncol Rep. 2025;54:148.
    PubMed     Abstract available
    
    
    October 2025
32. LIN Z, Chen Q, Chen Z, Peng T, et al
    Advances in the chemo?preventive effects and mechanisms of ursolic acid against lung cancer (Review).
    Oncol Rep. 2025;54:126.
    PubMed     Abstract available
    
    
    
33. FUJIYOSHI K, Sugihara R, Miyamoto N, Watanabe Y, et al
    Comprehensive genetic profiling using tissue and blood in locally advanced tumors.
    Oncol Rep. 2025;54:134.
    PubMed     Abstract available
    
    
    September 2025
34. DU J, Gong X, Huang R, Zheng B, et al
    Harnessing CRISPR/Cas9 to overcome targeted therapy resistance in non?small cell lung cancer: Advances and challenges (Review).
    Oncol Rep. 2025;54:111.
    PubMed     Abstract available
    
    
    
35. KIM MS, Kim MS
    TRPML3?mediated lysosomal Ca(2+) release enhances drug sequestration and biogenesis, promoting osimertinib resistance in non?small cell lung cancer.
    Oncol Rep. 2025;54:113.
    PubMed     Abstract available
    
    
    August 2025
36. ZINNAH KMA, Park SY
    [Corrigendum] Sensitizing TRAIL?resistant A549 lung cancer cells and enhancing TRAIL?induced apoptosis with the antidepressant amitriptyline.
    Oncol Rep. 2025;54:87.
    PubMed     Abstract available
    
    
    July 2025
37. YAN Y, Kong X, Jin X, Bu J, et al
    RNA?binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.
    Oncol Rep. 2025;54:74.
    PubMed     Abstract available
    
    
    June 2025
38. YUAN Q, Li X, Chen X, Xiao J, et al
    7?Difluoromethoxyl?5,4'?di?n?octylygenistein targets the STAT3 pathway by upregulating microRNA?152?3p expression to inhibit self?renewal and tumor growth in non?small cell lung carcinoma.
    Oncol Rep. 2025;53:66.
    PubMed     Abstract available
    
    
    May 2025
39. HU Y, Liu X, Yuan Z, He J, et al
    Induction of necroptosis in lung adenocarcinoma by miR?10b?5p through modulation of the PKP3/RIPK3/MLKL cascade.
    Oncol Rep. 2025;53:56.
    PubMed     Abstract available
    
    
    
40. LIN GB, Chen WT, Kuo YY, Liu HH, et al
    Thermal cycling?hyperthermia sensitizes non?small cell lung cancer A549 cells to EGFR tyrosine kinase inhibitor erlotinib.
    Oncol Rep. 2025;53:58.
    PubMed     Abstract available
    
    
    
41. ZHANG J, Qi S, Du Y, Dai H, et al
    Effect of quercetin on inhibiting gefitinib?activated non?small cell lung cancer?induced cell pyroptosis in cardiomyocytes via modulating mitochondrial autophagy mediated by the SHP2/ROS/AMPK/XBP?1/DJ?1 signaling pathway.
    Oncol Rep. 2025;53:57.
    PubMed     Abstract available
    
    
    April 2025
42. ZHANG L, Wang S, Wang L
    Pan?cancer analysis of oncogene SFXN1 to identify its prognostic and immunological roles in lung adenocarcinoma.
    Oncol Rep. 2025;53:50.
    PubMed     Abstract available
    
    
    February 2025
43. PENG Y, Li D, Wampfler JA, Luo YH, et al
    Targeted therapy?associated cardiotoxicity in patients with stage?IV lung cancer with or without cardiac comorbidities.
    Oncol Rep. 2025;53:25.
    PubMed     Abstract available
    
    
    
44. ZHOU S, Sun J, Zhu W, Yang Z, et al
    Hypoxia studies in non?small cell lung cancer: Pathogenesis and clinical implications (Review).
    Oncol Rep. 2025;53:29.
    PubMed     Abstract available
    
    
    January 2025
45. MUTO S, Homma MK, Kiko Y, Ozaki Y, et al
    Nucleolar casein kinase 2 alpha as a prognostic factor in patients with surgically resected early?stage lung adenocarcinoma.
    Oncol Rep. 2025;53:4.
    PubMed     Abstract available
    
    
    
46. WANG M, Chen X, Fu G, Ge M, et al
    [Retracted] Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS?mutated lung cancer cells.
    Oncol Rep. 2025;53:1.
    PubMed     Abstract available
    
    
    December 2024
47. WEI Q, Lin J, Lin Z, Yu N, et al
    GOLPH3 inhibition overcomes cisplatin resistance by restoring the glutathione/reactive oxygen species balance in the A549 non?small cell lung cancer cell line.
    Oncol Rep. 2024;52:170.
    PubMed     Abstract available
    
    
    
48. HU X, Zhang S, Zhang X, Liu H, et al
    HOXD1 inhibits lung adenocarcinoma progression and is regulated by DNA methylation.
    Oncol Rep. 2024;52:173.
    PubMed     Abstract available
    
    
    November 2024
49. GUI H, Nie Y, Yuan H, Jing Q, et al
    The combination of a PTP1B inhibitor, TNFR2 blocker, and PD?1 antibody suppresses the progression of non?small cell lung cancer tumors by enhancing immunocompetence.
    Oncol Rep. 2024;52:149.
    PubMed     Abstract available
    
    
    
50. KANAYAMA M, Yoneda K, Kuwata T, Mori M, et al
    Enhanced capture system for mesenchymal?type circulating tumor cells using a polymeric microfluidic device 'CTC?Chip' incorporating cell?surface vimentin.
    Oncol Rep. 2024;52:156.
    PubMed     Abstract available
    
    
    
51. GEORGAKOPOULOU VE, Lempesis IG, Trakas N, Sklapani P, et al
    Lung cancer and obesity: A contentious relationship (Review).
    Oncol Rep. 2024;52:158.
    PubMed     Abstract available
    
    
    October 2024
52. ZHOU M, Wei L, Lu R
    Emerging role of sirtuins in non?small cell lung cancer (Review).
    Oncol Rep. 2024;52:127.
    PubMed     Abstract available
    
    
    
53. WEI W, Zhao X, Zhu J, Zhang L, et al
    [Retracted] lncRNA?u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling.
    Oncol Rep. 2024;52:126.
    PubMed     Abstract available
    
    
    
54. MUNKHJARGAL B, Kondo K, Soejima S, Tegshee B, et al
    DNA methylation and mRNA expression of ZNF577 as biomarkers for the detection and prognosis of lung adenocarcinoma.
    Oncol Rep. 2024;52:131.
    PubMed     Abstract available
    
    
    August 2024
55. LI S, Wang H, Ma R, Wang L, et al
    [Retracted] Schisandrin B inhibits epithelial?mesenchymal transition and stemness of large?cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF?kappaB and p38 MAPK signaling pathways.
    Oncol Rep. 2024;52:102.
    PubMed     Abstract available
    
    
    July 2024
56. CHENG SH, Tu KY, Lee HH
    The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).
    Oncol Rep. 2024;52:96.
    PubMed     Abstract available
    
    
    June 2024
57. GAO Y, Zhang G, Liu J, Li H, et al
    [Retracted] Tissue?specific transplantation antigen P35B functions as an oncogene and is regulated by microRNA?125a?5p in lung cancer.
    Oncol Rep. 2024;51:76.
    PubMed     Abstract available
    
    
    February 2024
58. ZHANG F, Qi Y, Li J, Liu B, et al
    Activin A induces apoptosis of human lung adenocarcinoma A549 cells through endoplasmic reticulum stress pathway.
    Oncol Rep. 2024;51:29.
    PubMed     Abstract available
    
    
    
59. LU X, Ma S, Li Y, Pan Y, et al
    Identification of ITGB4 as a novel tumor promoting gene in lung adenocarcinoma (LUAD).
    Oncol Rep. 2024;51:30.
    PubMed     Abstract available
    
    
    
60. LOU H, Wu Z, Wei G
    CDC6 may serve as an indicator of lung adenocarcinoma prognosis and progression based on TCGA and GEO data mining and experimental analyses.
    Oncol Rep. 2024;51:35.
    PubMed     Abstract available
    
    
    January 2024
61. CHENG Z, Cui H, Wang Y, Yang J, et al
    The advance of the third?generation EGFR?TKI in the treatment of non?small cell lung cancer (Review).
    Oncol Rep. 2024;51:16.
    PubMed     Abstract available
    
    
    December 2023
62. LIU J, Zhang F, Wang J, Wang Y, et al
    MicroRNA?mediated regulation in lung adenocarcinoma: Signaling pathways and potential therapeutic implications (Review).
    Oncol Rep. 2023;50:211.
    PubMed     Abstract available
    
    
    November 2023
63. CHEN Z, Li P, Shen L, Jiang X, et al
    Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis.
    Oncol Rep. 2023;50:196.
    PubMed     Abstract available
    
    
    
64. WU Z, Liu S, Pang G, Jiang H, et al
    RNA?binding protein quaking 5 inhibits the progression of non?small cell lung cancer by upregulating netrin?4 expression.
    Oncol Rep. 2023;50:204.
    PubMed     Abstract available
    
    
    
65. TIAN C, Li J, Ren L, Peng R, et al
    [Retracted] MicroRNA?381 serves as a prognostic factor and inhibits migration and invasion in non?small cell lung cancer by targeting LRH?1.
    Oncol Rep. 2023;50:203.
    PubMed     Abstract available
    
    
    
66. ZHANG J, Darman L, Hassan MS, Von Holzen U, et al
    Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
    Oncol Rep. 2023;50:206.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum